US2018071260A1PendingUtilityA1

Methods of treating alpha adrenergic mediated conditions

Assignee: ALLERGAN INCPriority: Jun 9, 2008Filed: Nov 21, 2017Published: Mar 15, 2018
Est. expiryJun 9, 2028(~1.9 yrs left)· nominal 20-yr term from priority
A61P 29/00A61K 31/4174C07D 233/48C07D 233/50A61K 31/4168A61P 25/00A61K 31/40A61K 9/0053
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating gastritis in a mammal, the method comprising administering to the mammal in need of such treatment a pharmaceutically effective dose of N-(2,3-dichlorobenzyl)-4,5-dihydro-1H-imidazol-2-amine having the following structure: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein the dose is administered by an oral route. 
     
     
         3 . The method of  claim 2 , wherein the dose is orally administered in the form of a tablet, liquid, capsule or powder. 
     
     
         4 . The method of  claim 1 , wherein the dose is administered by a transdermal, parenteral, subcutaneous, intranasal, intrathecal, intramuscular, intravenous or intrarectal route. 
     
     
         5 . The method of  claim 1 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2018071260A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.